Actively Recruiting
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
Led by Peking University Cancer Hospital & Institute · Updated on 2025-12-02
30
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if treatment modality including albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules (SOX) and sintilimab works to treat locally advanced HER2-negative hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are: * To evaluate the perioperative efficacy of albumin-bound paclitaxel combined with sintilimab and SOX in the treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach * To evaluate the safety and long-term benefits of albumin-bound paclitaxel combined with sintilimab and SOX regimens in perioperative treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach Participants will: * Preoperative treatment with abumin-bound paclitaxel, SOX and sintilimab for 4 cycles * Radical surgery after 4-6 weeks of the preoperative treatment * Adjuvant treatment with albumin-bound paclitaxel, tegafur,gimeracil and oteracil porassium capsules and sintilimab for 4 cycles
CONDITIONS
Official Title
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed gastric hepatoid adenocarcinoma
- HER2 negative status confirmed by immunohistochemistry (score 0)
- Clinical stage II or III disease
- Expected to complete R0 surgical excision
- ECOG performance status of 0 or 1
- Generally in good health to tolerate perioperative treatment and surgery
- Voluntary participation in the study
You will not qualify if you...
- Presence of other malignant tumors except thyroid papillary carcinoma, facial basal cell carcinoma, or other low-grade malignancies
- Need for surgical intervention due to obstruction or bleeding as evaluated by clinicians
- dMMR/MSIH status
- Prior anti-tumor therapy before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Cancer Hospital & Institute
Beijing, China
Actively Recruiting
Research Team
A
Anqiang Wang, MD
CONTACT
J
Jialin Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here